SCHEMBL6104693

SCHEMBL6104693

COCOCCNS(=O)(=O)c1ccc(I)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.58
LMNA P02545 3/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
HPGD P15428 2/20 0.58
KDM4E B2RXH2 1/20 0.58
NPC1 O15118 1/20 0.58
MAPT P10636 1/20 0.58
RAB9A P51151 1/20 0.58
SIGMAR1 Q99720 4/20 0.52
ALOX15 P16050 1/20 0.52
HTT P42858 1/20 0.52
PKM P14618 2/20 0.48
MEN1 O00255 1/20 0.48
POLB P06746 1/20 0.48
TSHR P16473 1/20 0.48
KMT2A Q03164 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
MAPK1 P28482 1/20 0.48
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15522663 0.88 ALDH1A1 (0.62) ALDH1A1LMNASMN1; SMN2HPGDKDM4E
SCHEMBL3126117 0.87 ALDH1A1 (0.75) ALDH1A1LMNASMN1; SMN2HPGDKDM4E
SCHEMBL4028724 0.84 ALDH1A1 (0.61) ALDH1A1LMNASMN1; SMN2HPGDKDM4E
SCHEMBL15581459 0.82 ALDH1A1 (0.62) ALDH1A1LMNASMN1; SMN2HPGDKDM4E
SCHEMBL6595788 0.81 MAPK1 (0.71) ALDH1A1LMNASMN1; SMN2HPGDKDM4E
SCHEMBL6622577 0.78 ALDH1A1 (0.54) ALDH1A1LMNASMN1; SMN2HPGDKDM4E
SCHEMBL5096291 0.78 SIGMAR1 (0.55) ALDH1A1LMNASMN1; SMN2HPGDKDM4E
SCHEMBL6595668 0.77 ALDH1A1 (0.62) ALDH1A1LMNASMN1; SMN2KDM4ESIGMAR1
SCHEMBL5098898 0.77 ALDH1A1 (0.51) ALDH1A1LMNASMN1; SMN2HPGDKDM4E
SCHEMBL6622589 0.75 ALDH1A1 (0.50) ALDH1A1LMNASMN1; SMN2HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004033-A1 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation ASTRAZENECA AB 2006-01-05 US disclosed
US-6969714-B2 Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation ASTRAZENECA AB (SE) 2005-11-29 US disclosed
EP-1351958-B1 IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION ASTRAZENECA AB (SE) 2004-06-16 EP disclosed
US-20040014776-A1 Imidazolo-5-YL-2anilino-pyrimidines as agents for the inhibition of the cell proliffration ASTRAZENECA AB (SE) 2004-01-22 US disclosed
EP-1351958-A1 IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION AstraZeneca AB (SE) 2003-10-15 EP disclosed
WO-2002020512-A1 IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION ASTRAZENECA AB (SE) 2002-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004033-A1 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation MKI67, CCNI, CCNT1 ALDH1A1 1177/4885LMNA 574/4885SMN1; SMN2 2007/4885
US-20040014776-A1 Imidazolo-5-YL-2anilino-pyrimidines as agents for the inhibition of the cell proliffration CCNI, TYMP, MKI67 ALDH1A1 545/4885LMNA 764/4885SMN1; SMN2 2609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.